JP2020519230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519230A5 JP2020519230A5 JP2018564966A JP2018564966A JP2020519230A5 JP 2020519230 A5 JP2020519230 A5 JP 2020519230A5 JP 2018564966 A JP2018564966 A JP 2018564966A JP 2018564966 A JP2018564966 A JP 2018564966A JP 2020519230 A5 JP2020519230 A5 JP 2020519230A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- sequence
- peptide
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 11
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 230000003834 intracellular effect Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 230000003248 secreting effect Effects 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 claims 1
- 108091092195 Intron Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504120P | 2017-05-10 | 2017-05-10 | |
| US62/504,120 | 2017-05-10 | ||
| PCT/US2018/032018 WO2018209052A1 (en) | 2017-05-10 | 2018-05-10 | Enveloped virus resistant to complement inactivation for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519230A JP2020519230A (ja) | 2020-07-02 |
| JP2020519230A5 true JP2020519230A5 (enExample) | 2021-05-20 |
| JP7161940B2 JP7161940B2 (ja) | 2022-10-27 |
Family
ID=64105722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564966A Active JP7161940B2 (ja) | 2017-05-10 | 2018-05-10 | がんの治療のための、補体不活性化に耐性のエンベロープウイルス |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11274141B2 (enExample) |
| EP (1) | EP3621635A4 (enExample) |
| JP (1) | JP7161940B2 (enExample) |
| KR (3) | KR102662049B1 (enExample) |
| CN (3) | CN121343935A (enExample) |
| AU (1) | AU2018265258B2 (enExample) |
| BR (1) | BR112018075281A2 (enExample) |
| CA (1) | CA3026892A1 (enExample) |
| IL (1) | IL263979B2 (enExample) |
| MX (1) | MX2018015599A (enExample) |
| WO (1) | WO2018209052A1 (enExample) |
| ZA (1) | ZA201808040B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN112759654A (zh) * | 2019-11-06 | 2021-05-07 | 深圳普菲科生命科技有限公司 | 一种病毒囊膜蛋白装配系统及其方法和应用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| KR102789416B1 (ko) * | 2021-02-26 | 2025-04-03 | 신라젠(주) | 항암 바이러스 및 이의 용도 |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| KR20240003051A (ko) * | 2022-06-29 | 2024-01-08 | 신라젠(주) | Cd55 및 cd59를 동시 발현하는 항암 바이러스 |
| AU2023338427A1 (en) * | 2022-09-07 | 2025-04-03 | Sillajen, Inc. | Novel use of oncolytic virus |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| EP1314431B1 (en) | 1993-04-30 | 2008-07-16 | Wellstat Biologics Corporation | Purified compositions of Newcastle disease virus |
| JPH10313865A (ja) * | 1997-05-15 | 1998-12-02 | Deinabetsuku Kenkyusho:Kk | ヒト補体制御因子が呈示されたベクター |
| JP2002509695A (ja) | 1997-11-21 | 2002-04-02 | ゲセルシャフト フュア バイオテクノロギッシェフォーシュング エムベーハー（ゲーベーエフ） | 一本鎖ｄｎａ又は二本鎖ｄｎａ、コード化融合タンパク質，ウイルス，パッケージング細胞及びこれらの使用ヒト補体システムによる不活化に耐えるウイルスの開発 |
| ATE451466T1 (de) | 1997-12-22 | 2009-12-15 | Univ Tennessee Res Corp | Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält |
| AU752168B2 (en) * | 1998-04-02 | 2002-09-05 | Rigel Pharmaceuticals, Inc. | Peptides causing formation of compact structures |
| MXPA01010393A (es) | 1999-04-15 | 2004-04-02 | Pro Virus Inc | Tratamiento de neoplasmas con virus. |
| CA2505601C (en) | 2002-11-15 | 2014-10-28 | Musc Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| JP4956427B2 (ja) | 2004-07-21 | 2012-06-20 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | レンチウイルスベクターおよびその使用 |
| JP5050198B2 (ja) | 2006-09-05 | 2012-10-17 | 国立大学法人大阪大学 | ヒト補体制御因子発現遺伝子およびその利用 |
| US20100120628A1 (en) | 2007-02-06 | 2010-05-13 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| US20100120665A1 (en) | 2007-03-01 | 2010-05-13 | Advanced Vision Therapies, Inc. | Treatment of diseases characterized by inflammation |
| US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| EP2702157A1 (en) | 2011-04-29 | 2014-03-05 | Keygene N.V. | Glyphosate resistance enhancement |
| EP2704744B1 (en) | 2011-05-05 | 2019-04-24 | Wellstat ImmunoTherapeutics, LLC | Complement factor b analogs and their uses |
| BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
| SI3888674T1 (sl) * | 2014-04-07 | 2024-08-30 | Novartis Ag | Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19 |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| PH12017501834B1 (en) | 2015-04-06 | 2024-01-17 | Arcellx Inc | De novo binding domain containing polypeptides and uses thereof |
| GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| CN107708741A (zh) | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| CA3024653A1 (en) | 2016-05-19 | 2017-11-23 | Turnstone Limited Partnership | Pseudotyped oncolytic rhabdoviruses and their use in combination therapy |
-
2018
- 2018-05-10 US US16/303,729 patent/US11274141B2/en active Active
- 2018-05-10 CN CN202511447108.XA patent/CN121343935A/zh active Pending
- 2018-05-10 BR BR112018075281-9A patent/BR112018075281A2/pt unknown
- 2018-05-10 CN CN201880002553.7A patent/CN109414483B/zh active Active
- 2018-05-10 MX MX2018015599A patent/MX2018015599A/es unknown
- 2018-05-10 CN CN202511447107.5A patent/CN121343934A/zh active Pending
- 2018-05-10 KR KR1020187037869A patent/KR102662049B1/ko active Active
- 2018-05-10 IL IL263979A patent/IL263979B2/en unknown
- 2018-05-10 CA CA3026892A patent/CA3026892A1/en active Pending
- 2018-05-10 JP JP2018564966A patent/JP7161940B2/ja active Active
- 2018-05-10 KR KR1020257024807A patent/KR20250118857A/ko active Pending
- 2018-05-10 WO PCT/US2018/032018 patent/WO2018209052A1/en not_active Ceased
- 2018-05-10 AU AU2018265258A patent/AU2018265258B2/en active Active
- 2018-05-10 EP EP18798575.9A patent/EP3621635A4/en active Pending
- 2018-05-10 KR KR1020247013722A patent/KR102839445B1/ko active Active
- 2018-11-28 ZA ZA2018/08040A patent/ZA201808040B/en unknown
-
2022
- 2022-02-18 US US17/674,990 patent/US20220169701A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519230A5 (enExample) | ||
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| ES2307550T3 (es) | Di-u oligomero de un di-, tri-,tetra- o pentametro de proteinas de fusion recombinantes. | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| JP2019514373A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| JP2018515096A5 (enExample) | ||
| JP7161940B2 (ja) | がんの治療のための、補体不活性化に耐性のエンベロープウイルス | |
| CN104342453A (zh) | 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用 | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| RU2014135053A (ru) | Иммуногены для вакцинации против вич | |
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih | |
| KR20190056382A (ko) | 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도 | |
| CN114213548B (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| JP2014073123A (ja) | パラミクソウイルス科（Ｐａｒａｍｙｘｏｖｉｒｉｄａｅ）ファミリーのウイルスのＮタンパク質−対象タンパク質の融合タンパク質 | |
| ES2639307T3 (es) | Péptidos con propiedades potenciadoras de infección vírica y su uso | |
| RS63526B1 (sr) | Vakcine za virus gripa i njihove upotrebe | |
| JP2019530441A5 (enExample) | ||
| WO2022043449A1 (en) | Vaccines based on an antigen protein fused to a nanostructuring scaffold | |
| CN105143251B (zh) | 流感核蛋白疫苗 | |
| JP2013529178A5 (enExample) | ||
| RU2008138536A (ru) | Химерные вакцинные антигены против вируса классической чумы свиней | |
| JP2016520534A5 (enExample) | ||
| CA2991213A1 (en) | Recombinant virus like particles using bovine immunodeficiency virus gag protein | |
| US20250064873A1 (en) | TNFSF-L Fusion Proteins and Uses Thereof |